(Q37865422)

24 August 2017

1 reference

title

The dexamethasone drug delivery system: indications and evidence (English)

1 reference

24 August 2017

1 reference

1 reference

Nikolas J S London

1

1 reference

24 August 2017

Allen Chiang

series ordinal

2

1 reference

24 August 2017

Julia A Haller

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

12 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

28

1 reference

24 August 2017

5

1 reference

24 August 2017

351-366

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-011-0019-z

24 August 2017

0 references

cites work

High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

The use of intravitreal corticosteroids, evidence-based and otherwise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Corticosteroids in ophthalmology: past-present-future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Toxicity of high-dose intravitreal dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Management of macular edema from retinal vein occlusions: you can never have too many choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Complications of intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Noninfectious endophthalmitis associated with intravitreal triamcinolone injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Cell viability effects of triamcinolone acetonide and preservative vehicle formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

In vitro benzyl alcohol cytotoxicity: implications for intravitreal use of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

Measurement of the Actual Dose of Triamcinolone Acetonide Delivered by Common Techniques of Intravitreal Injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0019-Z

10.1007/S12325-011-0019-Z

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference